File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

TitleAntituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Authors
Issue Date2000
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2000, v. 31 n. 1, p. 201-206 How to Cite?
AbstractLiver toxicity is a common side effect of antituberculosis (anti-TB) drugs. We studied the differences in liver dysfunction observed during anti- TB treatment between hepatitis B virus carriers (HBV) and noncarriers. Three hundred twenty-four patients on anti-TB drugs were recruited and followed up for I year. Forty-three patients with HBV and 276 non-HBV patients were included for analysis. Liver function tests and viral markers were monitored monthly. Liver biopsy was requested whenever the alanine transaminase (ALT) was persistently abnormal. Eighty-six HBV carriers who were not given anti-TB drugs were chosen as a second control and evaluated prospectively. The incidence of liver dysfunction was significantly higher in HBV carriers given anti-TB drugs (34.9%) when compared to noncarriers (9.4%, P <.001) and with HBV carriers not given anti-TB drugs (8.1%, P < .001). For patients given anti-TB drugs, HBV carriers who developed liver dysfunction were younger (P = .011) and had more severe liver injury compared with noncarriers (P = .008). By multiple logistic regression analysis, age (P = .002) and hepatitis B infection (P < .001) were the only 2 significant risk factors for hepatotoxicity related to anti-TB therapy.
Persistent Identifierhttp://hdl.handle.net/10722/78231
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWu, PCen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorCheng, CCen_HK
dc.contributor.authorYew, WWen_HK
dc.contributor.authorWong, PCen_HK
dc.contributor.authorTam, CMen_HK
dc.contributor.authorLeung, CCen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:40:36Z-
dc.date.available2010-09-06T07:40:36Z-
dc.date.issued2000en_HK
dc.identifier.citationHepatology, 2000, v. 31 n. 1, p. 201-206en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78231-
dc.description.abstractLiver toxicity is a common side effect of antituberculosis (anti-TB) drugs. We studied the differences in liver dysfunction observed during anti- TB treatment between hepatitis B virus carriers (HBV) and noncarriers. Three hundred twenty-four patients on anti-TB drugs were recruited and followed up for I year. Forty-three patients with HBV and 276 non-HBV patients were included for analysis. Liver function tests and viral markers were monitored monthly. Liver biopsy was requested whenever the alanine transaminase (ALT) was persistently abnormal. Eighty-six HBV carriers who were not given anti-TB drugs were chosen as a second control and evaluated prospectively. The incidence of liver dysfunction was significantly higher in HBV carriers given anti-TB drugs (34.9%) when compared to noncarriers (9.4%, P <.001) and with HBV carriers not given anti-TB drugs (8.1%, P < .001). For patients given anti-TB drugs, HBV carriers who developed liver dysfunction were younger (P = .011) and had more severe liver injury compared with noncarriers (P = .008). By multiple logistic regression analysis, age (P = .002) and hepatitis B infection (P < .001) were the only 2 significant risk factors for hepatotoxicity related to anti-TB therapy.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAntitubercular Agents - adverse effectsen_HK
dc.subject.meshAspartate Aminotransferases - blooden_HK
dc.subject.meshBiopsyen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshDrug-Induced Liver Injuryen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B e Antigens - blooden_HK
dc.subject.meshHepatitis B, Chronic - complications - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver - pathology - physiopathologyen_HK
dc.subject.meshLiver Diseases - pathology - physiopathologyen_HK
dc.subject.meshLogistic Modelsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.titleAntituberculosis drug-related liver dysfunction in chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=31&issue=1&spage=201&epage=206&date=2000&atitle=Antituberculosis+drug-related+liver+dysfunction+in+chronic+hepatitis+B+infectionen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hep.510310129-
dc.identifier.pmid10613746-
dc.identifier.scopuseid_2-s2.0-0033960045en_HK
dc.identifier.hkuros48373en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033960045&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume31en_HK
dc.identifier.issue1en_HK
dc.identifier.spage201en_HK
dc.identifier.epage206en_HK
dc.identifier.isiWOS:000084550700029-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWu, PC=7403119323en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridCheng, CC=7404796652en_HK
dc.identifier.scopusauthoridYew, WW=7005934631en_HK
dc.identifier.scopusauthoridWong, PC=7403979916en_HK
dc.identifier.scopusauthoridTam, CM=7201442997en_HK
dc.identifier.scopusauthoridLeung, CC=7402612644en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats